Skip to content

Study of Pulmonary Artery Banding for the Improvement of Left Ventricular Function in Pediatric Heart Failure

A Comprehensive Research of Pediatric Heart Failure -- A Self-control Study of Pulmonary Artery Banding for the Improvement of Left Ventricular Function in Pediatric Heart Failure

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06039553
Enrollment
25
Registered
2023-09-15
Start date
2022-01-01
Completion date
2024-12-31
Last updated
2023-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure Congenital

Keywords

congenital heart disease, pulmonary artery banding

Brief summary

The goal of this observational study is to learn about the safety and effectiveness of pulmonary artery banding(PAB) therapy in pediatric heart failure(PHF) patients. The main questions it aims to answer are: * Can PAB therapy improve left ventricular(LV) function in PHF patients especially refractory PHF. * Can the complications caused by the PAB therapy be clinically acceptable? Participants underwent PAB therapy will be required to underwent echocardiography, electrocardiograms, complete blood counts, biochemical tests, and measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) follow-up before the initiation of PAB and at 1 month, 3 months, and 6 months after PAB surgery. Researchers will compare the LV function 6 months after PAB suergey and the preoperative ones to see if there is improvement.

Interventions

PROCEDUREpulmonary artery banding

Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.

Sponsors

Peking University First Hospital
CollaboratorOTHER
Beijing Children's Hospital
CollaboratorOTHER
China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 14 Years

Inclusion criteria

* patients younger than 14 years of age * congenital heart failure (LVEF\<55%, or LVFS\<25%)

Exclusion criteria

* single ventricle * congenital heart disease without anatomical correction * Patients with heart failure requiring ventricular assist or cardiac synchronization therapy * Patients with severe pulmonary hypertension (pulmonary arterial pressure \>6 Wood·U) * Patients with severe liver and kidney failure * Patients who are allergic to related medications * Patients with symptomatic hypotension who cannot tolerate related drugs * Refuse to sign the informed consent or refuse to participate in this experiment

Design outcomes

Primary

MeasureTime frameDescription
the recurrence rate of heart failureafter 6 months of PAB surgeryDuring follow-up visits, echocardiographic examination is conducted to measure the left ventricular function. If LVEF falls under 55%, it is recorded as a recurrence.

Secondary

MeasureTime frameDescription
NT-proBNP levelafter 6 months of PAB surgeryThe trend in NT-proBNP levels.
Incidence rate of drug adverse reactionsafter 6 months of PAB surgeryThe incidence of abnormalities in complete blood count, electrolytes, liver and kidney function, and cardiac enzymes.
Readmission rate for heart failureafter 6 months of PAB surgeryDuring follow-up visits, readmission for heart failure will be recorded.

Countries

China

Contacts

Primary ContactKai Ma, PhD
drmakaifw@yahoo.com+86 15901428497
Backup ContactZheng Dou, PhD
drdouzheng@163.com+86 18810673618

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026